Antibody-Drug Conjugates Show Efficacy in Advanced HER2-Positive and Low-Expressing Gastric Cancer
Gastric cancer ranks as the fifth most common gastrointestinal cancer worldwide in terms of incidence and mortality, posing a particularly ...
Gastric cancer ranks as the fifth most common gastrointestinal cancer worldwide in terms of incidence and mortality, posing a particularly ...
Researchers at Vanderbilt-Ingram Cancer Center generated a large-scale transcriptomic atlas of breast cancer, integrating data from over 7,600 tumors to ...
Researchers found that TFAP2A drives stemness, metastasis, and paclitaxel resistance in aggressive breast cancer models through KDM4B transcriptional regulation.
A systematic review and meta-analysis of eight randomized controlled trials demonstrates that adding pertuzumab to standard therapies significantly improves progression-free ...
A perspective in Amino Acids argues that hormone receptor status defines distinct biological subtypes within HER2-positive breast cancer, influencing survival ...
An analysis of 5,318 early breast cancer patients found that 2 percent developed brain metastases at first recurrence, with triple-negative ...
A study in Cancer Pathogenesis and Therapy finds ITGA3 expression in 85.2% of breast cancer specimens and links high levels ...
A retrospective study of 103 patients with HER2-positive de novo metastatic breast cancer found that those who underwent breast surgery ...
A retrospective study of 138 premenopausal women with hormone receptor-positive, HER2-positive breast cancer found no independent survival benefit from adding ...
A study of more than 1,000 young breast cancer patients finds that lower income and younger age are linked to ...
A machine learning study of 351 breast cancer patients shows that MRI radiomics features from both the tumor and its ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.